Comparación crítica de los documentos de sociedades científicas sobre la amiloidosis cardíaca. Revisión de actualización de JACC
Claudio Rapezzia,b, Alberto Aimoc,d, Matteo Serenellia, Andrea Barisonc,d, Giuseppe Vergaroc,d, Claudio Passinoc,d, Giorgia Panichellac, Gianfranco Sinagrae, Marco Merloe, Marianna Fontanaf, Julian Gillmoref, Candida Cristina Quartag, Mathew S. Maurerh, Michelle M. Kittlesoni, Pablo Garcia-Paviaj,k,l, Michele Emdinc,d
a Cardiologic Centre, University of Ferrara, Cona, Italia.
b Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italia.
c Institute of Life Sciences, Scuola Superiore Sant´Anna, Pisa, Italia.
d Cardiology Division, Fondazione Toscana Gabriele Monasterio, Pisa, Italia.
e Cardiovascular Department, Azienda Ospedaliero-Universitaria «Ospedali Riuniti» of Trieste, Trieste, Italia.
f National Amyloidosis Centre, Division of Medicine, Royal Free Hospital, University College London, Londres, Reino Unido.
g Alexion Pharmaceuticals, Stockley Park, Uxbridge, Reino Unido.
h European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart.
h Cardiac Amyloidosis Program, Centre for Advanced Cardiac Care, NewYork-Presbyterian Hospital, Columbia University Irving Medical Center, Nueva York, Nueva York, Estados Unidos.
i Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, Estados Unidos.
j Heart Failure and Inherited Cardiac Diseases Unit, Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, CIBERCV, Madrid, España.
k Universidad Francisco de Vitoria, Pozuelo de Alarcón, España.
l European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart.
